Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients to Evaluate Efficacy and Safety

NCT06477939 is registered in ClinicalTrials.gov with Institut de cancérologie Strasbourg Europe as lead sponsor.

NCT NCT06477939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06477939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients to Evaluate Efficacy and Safety
Lead sponsor
Institut de cancérologie Strasbourg Europe
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 1, 2025
Completion date
December 31, 2032
Enrollment
554 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma